On July 4, during the “2025 DEMO WORLD Enterprise Open Innovation and Venture Capital Conference” in Shanghai, CYZone officially released the “CYZONE 2025 CHINA GLOBAL NEW FORCES TOP 100” list. METiS Technologies was selected into the Top 100 and recognized as a “Global leader in nanomaterial innovation.”
This selection adopted a method of “research visits + expert jury review.” After data verification, research analysis, and evaluation of the applicant companies, combined with multiple dimensions such as public data and performance, localization layout, and global market influence, the final list of the “2025 Top 100 Emerging Globalization Companies” was determined.
The selection committee stated that the selected “growth enterprises” “have not only already achieved commercial breakthroughs in overseas markets but also demonstrated strong growth potential in globalization strategy and technological influence.”
At the same time, METiS Technologies was also recognized as a “Day One Global” enterprise. This list highlighted the unique perspective of “Day One Global” enterprises, emphasizing startup pioneers that possessed a global vision and international strategy from the very beginning. Among this year’s list, 24 companies were designated as “Day One Global.” These companies built systemic advantages for global competition at their inception, aiming to develop business and expand markets on a global scale, rather than being confined to local markets.
Since its founding, globalization and AI have been part of the DNA of METiS Technologies. The company has consistently focused on AI-driven nanodelivery innovation. With its independently developed AI technology platform, combined with high-throughput screening and experimental platforms, METiS continues to break through the blind spots of traditional nanodelivery exploration and steadily deepen its proprietary data and patent barriers.
At present, METiS has achieved precise targeted delivery capabilities for key tissues such as the liver, lungs, muscle, and central nervous system. Meanwhile, it is advancing multiple pipelines across metabolism, central nervous system, oncology, and autoimmunity. Its fastest-moving self-developed pipeline has already successfully completed Phase III clinical trials.
